Le Lézard
Classified in: Health, Science and technology, Business
Subject: LIC

PreventionGenetics selected to join Concert Genetics' Preferred Laboratory Network


MARSHFIELD, Wis., Jan. 19, 2021 /PRNewswire/ -- With more than 150,000 genetic tests available, at least 6.9 codes per claim and thousands of medical policies1,2, it's virtually impossible for providers and payers to keep up with the complex and ever-changing world of genetic testing. Today, PreventionGenetics joins Concert Genetics' Preferred Laboratory Network, which brings health plans and preferred laboratories together to ensure that the quality, pricing and service information needed for decision-making is at the forefront and eases the administrative burden involved in insurance claims processing for genetic testing.  

"PreventionGenetics has always offered transparent pricing in an effort to eliminate the misuse of healthcare dollars," said James Weber, PhD, President of PreventionGenetics. "Joining the preferred laboratory network furthers that mission and allows us to continue to build trusted relationships with health plans to ensure high quality testing is provided to patients at a fair cost."

Concert's Preferred Laboratory Network systematizes the collection and comparison of laboratory quality information and brings transparency to the genetic testing market. The network also streamlines the administrative coordination between plans and labs by helping to ensure the correct coding and coverage policy for tens of thousands of genetic tests are in place and followed. This is especially important given widespread coding variability, high denial rates, and growing use of costly interventions such as prior authorization.

"Today, administrative challenges and confusion stifle productive collaboration between health plans and leading laboratories. Patients pay the price, in both quality and cost. This network is designed to change that." said Rob Metcalf, CEO of Concert Genetics, in the press release announcing the program.

About PreventionGenetics
Founded in 2004 and located in Marshfield, Wisconsin, PreventionGenetics is a CLIA and ISO 15189:2012 accredited laboratory. PreventionGenetics delivers clinical genetic testing of the highest quality at fair prices with exemplary service to people around the world. PreventionGenetics provides tests for nearly all clinically relevant genes including a whole genome sequencing test and whole exome sequencing test.

About Concert Genetics
Concert Genetics is a software and managed services company that provides the digital infrastructure for reliable and efficient management of genetic testing and precision medicine. Concert's genetic testing management capabilities leverage a proprietary database of the U.S. clinical genetic testing market, market-leading expertise, and a technology platform that supports genetic test ordering, resulting, coding, coverage, and payment integrity.

1 Coding Variability in Genetic Testing. Concert Genetics. Sept. 5, 2019. www.concertgenetics.com/resources/coding-variability-in-genetic-testing/
2 Concert Genetics Benefit Program: www.concertgenetics.com/genetics-benefit-program/ 

Media Contact: Kristina Hamill, 715-3870484 x332, [email protected]

SOURCE PreventionGenetics


These press releases may also interest you

at 05:15
Every year in Quebec, more than 2,000 young people leave the care of the Director of Youth Protection (DYP) as they approach the age of majority. For youth under the care of the DYP, turning 18 means having to become independent quickly, with little...

at 03:00
ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, today announced an oral presentation at the upcoming Oligonucleotide & Peptide Therapeutics (TIDES) Conference...

at 02:32
With every successive year, the lines between medical devices and consumer electronics become increasingly blurred ? medtech companies seek to expand their reach beyond patients, and consumer electronics companies have targeted medical applications...

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....



News published on and distributed by: